Treatment of long bone non-unions with polytherapy: Indications and clinical results

Injury

Volumn 42, Issue 6, 2011, Pages 587-590

  Calori, G M ^a   Mazza, E ^a   Colombo, M ^a   Ripamonti, C ^a   Tagliabue, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Autologous bone graft; BMPs; Growth factors; Long bone non unions; Mesenchymal stem cells; Multi approach; Polytherapy

Indexed keywords

OSTEOCALCIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1;

ARTICLE; BONE DEVELOPMENT; BONE GRAFT; CANCELLOUS BONE; DONOR SITE; HUMAN; LONG BONE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PSEUDARTHROSIS; THERAPY EFFECT; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME;

BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; COMBINED MODALITY THERAPY; FRACTURE HEALING; FRACTURES, UNUNITED; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; TISSUE SCAFFOLDS;

EID: 79957874672     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/j.injury.2011.03.046     Document Type: Article

References (85)

1. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury 2007;38(Suppl. 1):S49-62.
2. Bae HW, Zhao L, Kanim LE, et al. Intervariability and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine 2006;31(12):1299-306. (Pubitemid 43833072)
3. Betz OB, Betz VM, Nazarian A, et al. Delayed administration of adenoviral BMP-2 vector improves the formation of bone in osseous defects. Gene Ther 2007;(13):1039-44. (Pubitemid 46965273)
4. Blokhuis TJ, Lindner T. Allograft and bone morphogenetic proteins: an overview. Injury 2008;39(Suppl. 2):S33-36.
5. Burastero G, Scarfì S, Ferraris C, et al. The association of human mesenchymal stem cells with BMP-7 improves bone regeneration of critical-size segmental bone defects in athymic rats. Bone 2010;47(1):117-26.
6. Burastero G, Sessarego N, Grappiolo G, et al. Association of ex-vivo expanded human mesenchymal stem cells and rhBMP-7 is highly effective in treating femoral defects in rats. J Orthop Trauma 2007;8:49-54. (Pubitemid 46421583)
7. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 2005;87(6):1205-12.
8. Calori GM, Albisetti W, Agus A, et al. Risk factors contributing to fracture nonunions. Injury 2007;38(Suppl. 2):S11-18.
9. Calori GM, Donati D, Di Bella C, Tagliabue L. Bone morphogenetic proteins and tissue engineering: future directions. Injury 2009;40(Suppl. 3):S67-76.
10. Calori GM, Phillips M, Jeetle S, et al. Classification of non-union: need for a new scoring system? Injury 2008;39(Suppl. 2):S59-63.
11. Calori GM, Tagliabue L, Gala L, et al. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomized clinical study on 120 patients. Injury 2008;39(12):1391-402.
12. Carreon LY, Glassman SD, Anekstein Y, Puno RM. Platelet gel (AGFs) fails to enhance fusion rates in instrumented posterolateral fusion. Spine 2005;30(9):243-6.
13. Celeste AJ, Iannazzi JA, Taylor RC, et al. Identification of transforming growth factor family members present in bone inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990;87:9843-7. (Pubitemid 120016540)
14. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004;22(4):233-41. (Pubitemid 40136452)
15. Connolly JF. Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis. Clin Orthop Relat Res 1998;355S:257-66.
16. Crowley DJ, Kanakaris NK, Giannoudis PV. Femoral diaphyseal aseptic nonunions: is there an ideal method of treatment? Injury 2007;38(Suppl. 2):S55-63.
17. De Long WG, Einhorn TA, Koval K, et al. Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am 2007;89(3):649-58. (Pubitemid 46365369)
18. Dimitriou R, Dahabreh Z, Katsoulis E, et al. Application of recombinant BMP-7 on persistent upper and lower limb non-unions. Injury 2005;36S:S51-59.
19. Dinopoulos H, Giannoudis PV. (iv) The use of bone morphogenetic proteins (BMPs) in long-bone non-unions. Curr Orthop 2007;21:268-79. (Pubitemid 47495968)
20. Drosos GI, Kazakos KI, Kouzoumpasis P, Verettas DA. Safety and efficacy of commercially available demineralized bone matrix preparations: a critical review of clinical studies. Injury 2007;38(Suppl. 4):S13-21.
21. Drosse I, Volkmer E, Capanna R, et al. Tissue engineering for bone defect healing: an update on a multi-component approach. Injury 2008;39(Suppl. 2):S9-20.
22. Einhorn TA, Lane JM, Burstein AH, et al. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. J Bone Joint Surg Am 1984;66(2):274-9. (Pubitemid 14150394)
23. Einhorn TA. Clinical applications of recombinant human BMPs: early experience and future development. J Bone Joint Surg Am 2003;85(Suppl. 3):82-8. (Pubitemid 36957902)
24. Ekrol I, Hajducka C, Court-Brown C, McQueen MM. A comparison of RhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of the distal radius. Injury 2008;39(Suppl. 2):S73-82.
25. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (BMP-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83(Suppl. 1):S151-158.
26. Gerard D, Carlson ER, Gotcher JE, Jacobs M. Effects of platelet-rich plasma at the cellular level on healing of autologous bone-grafted mandibular defects in dogs. J Oral Maxillofac Surg 2007;65(4):721-7. (Pubitemid 46412602)
27. Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. Injury 2007;38(Suppl. 4):S3-6.
28. Giannoudis PV, Einhorn TA, Schmidmaier G, Marsh D. The diamond concept: open questions. Injury 2008;39(Suppl. 2):S5-8.
29. Giannoudis PV, Kanakaris NK, Dimitriou R, et al. The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res 2009;467(12):3239-48.
30. Giannoudis PV, Kanakaris NK, Einhorn TA. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos Int 2007;18(12):1565-81. (Pubitemid 47620320)
31. Giannoudis PV, Psarakis S, Kanakaris NK, Pape HC. Biological enhancement of bone healing with bone morphogenetic protein-7 at the clinical setting of pelvic girdle non-unions. Injury 2007;38(Suppl. 4):S43-48.
32. Giannoudis Pv. Tzioupis C, Almalki T, Buckley R. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective. Injury 2007;38(Suppl. 1):S90-99.
33. Giannoudis PV, Tzioupis C. Clinical applications of BMP-7. The UK perspective. Injury 2005;36S:S47-50.
34. Goulet JA, Senunas LE, DeSilva GL, Greenfield ML. Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res 1997;339:75-81.
35. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84A(12):2123-34.
36. Gruber R, Kandler B, Fischer MB, Watzek G. Osteogenic differentiation induced by bone morphogenetic proteins can be suppresses by platelet-released supernatant in vitro. Clin Oral Implants Res 2006;17(2):188-93.
37. Gupta AR, Shah NR, Patel TC, Grauer JR. Perioperative and long-term complications of iliac crest bone graft harvesting for spinal surgery: a quantitative review of the literature. Intern Med J 2001;8(3):163-6. (Pubitemid 33026943)
38. Hakimi M, Jungbluth P, Sager M, et al. Combined use of platelet-rich plasma and autologous bone grafts in the treatment of long bone defects in mini-pigs. Injury 2010;41(7):811-7.
39. Hamanishi C, Yoshii T, Totani Y, Tanaka S. Bone mineral density of lengthened rabbit tibia is enhanced by transplantation of fresh autologous bone marrow cells. Clin Orthop 1994;303:250-5. (Pubitemid 24173814)
40. Hernigou P, Mathieu G, Poignard A, et al. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am 2006;88(Suppl. 1 (Pt2)):322-7.
41. Hernigou P, Poiguard A, Beaujean F, Rouard H. Percutaneous autologous bone marrow grafting for non-unions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005;87(7):1430-7. (Pubitemid 40917741)
42. Huang Z, Ren PG, Ma T, et al. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010;51(3):305-10.
43. Jacobsen KA, Al-Aql ZS, Wan C, et al. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 2008;23(5):596-609. (Pubitemid 351575014)
44. Kalen A, Wahlström O, Linder CH, Magnusson P. The content of bone morphogenetic proteins in platelets varies greatly between different platelet donors. Biochem Biophys Res Commun 2008;375:261-4.
45. Kanakaris NK, Calori GM, Verdonk R, et al. Application of BMP-7 to tibial nonunions: a 3-year multicenter experience. Injury 2008;39(Suppl. 2):S83-90.
46. Kanakaris NK, Lasanianos N, Calori GM, et al. Application of bone morphogenetic proteins to femoral non-unions: a 4-year multicentre experience. Injury 2009;S3:S54-S60.
47. Kanakaris NK, Paliobeis C, Manidakis N, Giannoudis PV. Biological enhancement of tibial diaphyseal aseptic non-unions: the efficacy of autologous bone grafting. BMPs and reaming by-products. Injury 2007;38(Suppl. 2):S65-75.
48. Keramaris NC, Calori GM, Nikolaou VS, et al. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008;39(S2):S45-S57.
49. Laurencin CT, Einhorn TA, Lyons K. Fracture repair: challenges and opportunities. J Bone Joint Surg Am 2008;90(Suppl. 1):1-2. (Pubitemid 351329112)
50. Lieberman JR, Daluski A, Einhorn TA. The role of growth factors in the repair of bone. biology and clinical applications. J Bone Joint Surg Am 2002;84A(6):1032-44.
51. Mahendra A, Maclean AD. Available biological treatments for complex nonunions. Injury 2007;38(Suppl. 4):S7-12.
52. Marx RE. Platelet rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96. (Pubitemid 38451232)
53. Matthews SJ, Nikolaou VS, Giannoudis PV. Innovations in osteosynthesis and fracture care. Injury 2008;39(8):827-38.
54. Mc Kee MD. Recombinant human bone morphogenetic protein-7: applications for clinical trauma. J Orthop Trauma 2005;19(Suppl. 10):S26-28.
55. Muschler GF, Midura RJ. Connective tissue progenitors: practical concepts for clinical applications. Clin Orthop Relat Res 2002;395:66-80. (Pubitemid 34136658)
56. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997;79(11):1699-709. (Pubitemid 27508530)
57. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001;19(1):117-25. (Pubitemid 32288644)
58. Nishida S, Endo N, Yamagiwa H, et al. Number of osteoprogenitor cells in human bone marrow markedly decreases after skeletal maturation. J Bone Miner Metab 1999;17(3):171-7. (Pubitemid 29403926)
59. Papathanasopoulos A, Giannoudis PV. Biological considerations of mesenchymal stem cells and endothelial progenitor cells. Injury 2008;39(Suppl. 2):S21-32.
60. Pountos I, Corscadden D, Emery P, Giannoudis PV. Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. Injury 2007;38(Suppl. 4):S23-33.
61. Ranly DM, Lohmann CH, Andreacchio D, Schwartz Z. Platelet-rich plasma inhibits demineralized bone matrix-induced bone formation in nude mice. J Bone Joint Surg Am 2007;89(1):139-47. (Pubitemid 46059153)
62. Roldan JC, Jepsen S, Miller J, et al. Bone formation in the presence of PRP vs. BMP7. Bone 2004;34:80-90.
63. Ronga M, Baldo F, Zappalà G, Cherubino P. Recombinant human bone morphogenetic protein-7 for treatment of long bone non-union: an observational, retrospective, non-randomized study of 105 patients. Injury 2006;37(Suppl. 3):51-6.
64. Schmidmaier G, Capanna R, Wildemann B, et al. Bone morphogenetic proteins in critical-size bone defects: what are the options? Injury 2009;40(Suppl. 3): S39-43.
65. Schmidmaier G, Schwabe P, Strobel C, Wildemann B. Carrier systems and application of growth factors in orthopaedics. Injury 2008;39(Suppl. 2):S37-43.
66. Schmidmaier G, Schwabe P, Wildemann B, Haas NP. Use of bone morphogenetic proteins for treatment of non-unions and future perspectives. Injury 2007;38(Suppl. 4):S35-41.
67. Sen MK, Miclau T. Autologous iliac crest bone graft: should it still be the gold standard for treating nonunions? Injury 2007;38(Suppl. 1):S75-80.
68. Sharma S, Garg NK, Veliath AJ, et al. Percutaneous bone-marrow grafting of osteotomies and bony defects in rabbits. Acta Orthop Scand 1992;63:166-9.
69. Shen B, Wei A, Whittaker S, et al. The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro. J Cell Biochem 2010;109(2):406-16.
70. Smith SE, DeLee JC, Ramamurthy S. Ilioinguinal neuralgia following iliac bone-grafting. Report of two cases and review of the literature. J Bone Joint Surg Am 1984;66(8):1306-8. (Pubitemid 15206115)
71. Stylios G, Wan T, Giannoudis P. Present status and future potential of enhancing bone healing using nanotechnology. Injury 2007;38(Suppl. 1):S63-74.
72. Kadiyala S, Jaiswal N, Bruder SP. Culture-expanded, bone marrow-derived mesenchymal stem cells can regenerate a critical-sized segmental bone defect. Tissue Engineering. Summer 1997;3(2):173-85. (Pubitemid 27271095)
73. Takigami H, Kumagai K, Latson L, et al. Bone formation following OP-1 implantation is improved by addition of autogenous bone marrow cells in a canine femur defect model. J Orthop Res 2007;25(10):1333-42. (Pubitemid 47523363)
74. Termaat MF, Den Boer FC, Bakker FC, et al. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 2005;87(6):1367-78.
75. Tsiridis E, Upadhyay N, Giannoudis P. Molecular aspects of fracture healing which are the important molecules? Injury 2007;38(Suppl. 1):S11-25.
76. Tzioupis C, Giannoudis PV. Prevalence of long-bone non-unions. Injury 2007;38(Suppl. 2):S3-9.
77. Uludag H, Gao T, Porter TJ, et al. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am 2001;83(Suppl. 1 (Pt 2)):S128-135.
78. Vaibhav B, Nilesh P, Vikram S, Anshul C. Bone morphogenic protein and its application in trauma cases: a current concept update. Injury 2007;38:1227-35. (Pubitemid 350046549)
79. Veillette CJ, McKee MD. Growth factors: BMPs, DBMs, and buffy coat products: are there any proven differences amongst them? Injury 2007;38(Suppl. 1):S38-48.
80. Wang YQ, Luk JM, Chu AC, et al. TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. Biochem Biophys Res Commun 2006;341(1):239-44. (Pubitemid 43117410)
81. Weber BG, Cech O. Pseudoarthrosis: Pathology, Biomechanics, Therapy, Results. Berne, Switzerland: Hans Huber Medical Publisher; 1976.
82. Weiner BK, Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine 2003;28(17):1968-71.
83. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Develop 1992;32:160-7.
84. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma 1989;33:192-5.
85. Zimmermann G, Wagner C, Schmeckenbecher K, et al. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury 2009;40(Suppl. 3):S50-53.